- Symrise achieved €4,929m in reported revenues for 2025, with a 2.8% organic sales growth.
- Adjusted EBITDA for 2025 was €1,081 million, with a margin of 21.9%.
- Symrise launched a share buyback program up to €400 million, active from February to October 2026.
- Non-cash impairments included €148 million for Terpene business and €150 million for Swedencare.
Financial Performance
In 2025, Symrise reported €4,929 million in revenues, achieving 2.8% organic sales growth. Adjusted EBITDA reached €1,081 million, with a margin of 21.9%, driven by €50 million in cost savings and efficiency gains.
Segment Highlights
The Taste, Nutrition & Health segment saw 2.6% organic growth, with Food & Beverage leading. The Scent & Care segment recorded 3.2% organic growth, driven by Fragrance. Both segments improved their adjusted EBITDA margins.
Strategic Initiatives
Symrise launched a €400 million share buyback program and proposed a dividend increase to €1.25 per share. The ONE SYM Transformation program progressed, focusing on growth, efficiency, and digitalization.
Outlook and Targets
For 2026, Symrise targets 2.0% to 4.0% organic sales growth and an adjusted EBITDA margin of 21.5% to 22.5%. Medium-term goals include a 5% to 7% organic sales growth CAGR and a Business Free Cash Flow margin above 14%.
